Axsome Q1 revenue $191.2M (+57% YoY); Auvelity approved for Alzheimer's agitation

Axsome Therapeutics, Inc.

2026-Q1 EPS reported -$1.26 revenue$191,203,000

Total net product revenue $191.2M (+57% YoY); Auvelity $153.2M (+59%), Sunosi $33.9M (+34%), Symbravo $4.1M.
Net loss $64.5M ($1.26/share) vs $59.4M ($1.22/share) YoY; cash $305.1M at March 31, 2026.
FDA approved Auvelity for agitation in Alzheimer's disease (April 2026); full commercial launch expected June 2026.
NDA submitted for AXS-12 (cataplexy in narcolepsy); pipeline expanded with AXS-20 (balipodect) for schizophrenia/Tourette.
Cash guidance: current resources sufficient to fund operations into cash flow positivity.

item 2.02 item 8.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Earnings Releases SEC 8-K Item 2.02 confidence 0.95

Axsome Therapeutics, Inc. reported first quarter of 2026 results: revenue $191.2 million, net income $(64.5) million, EPS $(1.26) per share.

Period: first quarter of 2026
Revenue: $191.2 million
Net income: $(64.5) million
EPS: $(1.26) per share
Result: reported results

Exact text from the filing

Total net product revenue was $191.2 million for the first quarter of 2026, representing 57% year-over-year growth.

View on SEC.gov

1427 earnings releases filed in the last 30 days. Browse all earnings releases →

Axsome Therapeutics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-202506

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.